| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:18626888 | IVTH | 0.00000005 - 0.0001 M | 0.00001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000005 - 0.0001 M | 0.00001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:30853599 | IVR | 0.25 % | 0.25 % | Decreased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVR | 0.25 % | 0.25 % | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Altered estrogen levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects cholesterol biosynthesis in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Increased triglycerides level in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 % | 0.25 % | Affects cholesterol transport in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 % | 0.025 % | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 % | 0.025 % | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 % | 0.025 % | Affects cholesterol transport in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated pertur | |
| IVR | 0.025 % | 0.025 % | Affects cholesterol metabolism | ||
| IVR | 0.025 % | 0.025 % | Decreased testis weights in offspring | ||
| IVR | 0.025 % | 0.025 % | Altered estrogen levels in offspring | ||
| IVR | 0.025 % | 0.025 % | Affects cholesterol transport | ||
| IVR | 0.025 % | 0.025 % | Affects steroidogenesis in offspring | ||
| IVR | 0.025 % | 0.025 % | Affects steroidogenesis | ||
| IVR | 0.025 % | 0.025 % | Increased cholesterol levels | ||
| IVR | 0.025 % | 0.025 % | Affects expression of estrogen receptor-beta (ER-beta) |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.